The Latest Breaking News from Pfizer

With the Food and Drug Administration’s Aug. 21, 2023, approval of the first vaccine against respiratory syncytial virus, or RSV, for use during late pregnancy, the U.S. will soon have a major new tool at its disposal to protect infants against the highly contagious virus.

There are now RSV vaccines approved for older adults and for pregnant people, and antibody shots (not vaccines) available for babies. What's the difference?

If you thought social media had a hand in getting Trump elected, watch what happens when you throw AI into the mix

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

A new method called ‘skeletal editing’ offers a hugely simplified way to alter matter, paving the way for world-changing innovations in personalised medicine and sustainable plastics

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

A panel of U.S. health advisers is recommending that babies get a new drug to protect them against a respiratory virus

Medical journals describe all-cause mortality in randomized controlled trials (RCTs) 

 Evidence the FDA used for those decisions violates at least three safety and efficacy standards from earlier FDA publications